Bioatla Stock Quote Today

BCAB -  USA Stock  

USD 10.11  0.83  8.94%

Market Performance
0 of 100
Odds Of Distress
Over 62
Bioatla is trading at 10.11 as of the 27th of January 2022, a 8.94% increase since the beginning of the trading day. The stock's open price was 9.28. Bioatla has more than 62 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Bioatla are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of July 2021 and ending today, the 27th of January 2022. Click here to learn more.
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. The company was founded in 2007 and is based in San Diego, California. Bioatla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 35.34 M outstanding shares of which 3.09 M shares are currently shorted by private and institutional investors with about 12.37 trading days to cover. More on Bioatla

Bioatla Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Bioatla's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bioatla or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Bioatla generated a negative expected return over the last 90 days
Bioatla has high historical volatility and very poor performance
Bioatla has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 250 K. Net Loss for the year was (79.43 M) with loss before overhead, payroll, taxes, and interest of (19.5 M).
Bioatla currently holds about 269.92 M in cash with (55.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.33.
Bioatla has a frail financial position based on the latest SEC disclosures
Roughly 73.0% of the company shares are held by institutions such as insurance companies
Latest headline from investingnews.com: AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA BIOTECHNOLOGIES WILL RECEIVE THE SECOND AMGEN GOLDEN TICKET - InvestingNews.com
Bioatla Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Bioatla SEC Filings
Bioatla SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameBioatla
Thematic Classification
Currently Active Investing Idea (view all)
  Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Bioatla report their recommendations after researching Bioatla's financial statements, talking to executives and customers, or listening in on Bioatla's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Bioatla. The Bioatla consensus assessment is calculated by taking the average forecast from all of the analysts covering Bioatla.
Strong Buy3 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Bioatla based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Bioatla financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares7.8 M7.6 M
Fairly Up
Decreasing
Slightly volatile
Weighted Average Shares Diluted7.8 M7.6 M
Fairly Up
Decreasing
Slightly volatile
Total Assets303.9 M281.7 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities37 M31.5 M
Fairly Up
Decreasing
Stable
Current Assets298.6 M276.8 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities32.7 M37.1 M
Fairly Down
Increasing
Slightly volatile
Total Debt630 K613.8 K
Fairly Up
Decreasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.00280.0027
Fairly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Bioatla's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Financial Strength
Bioatla's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Bioatla's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bioatla's financial leverage. It provides some insight into what part of Bioatla's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Bioatla's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Bioatla deploys its capital and how much of that capital is borrowed.
Liquidity
Bioatla cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 682 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Bioatla has a current ratio of 5.93, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(35.28 Million)Share
Bioatla (BCAB) is traded on NASDAQ Exchange in USA. It is located in 11085 Torreyana Road and employs 36 people. Bioatla is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 371.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bioatla's market, we take the total number of its shares issued and multiply it by Bioatla's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Bioatla conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 35.34 M outstanding shares of which 3.09 M shares are currently shorted by private and institutional investors with about 12.37 trading days to cover. Bioatla currently holds about 269.92 M in cash with (55.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.33.
Check Bioatla Probability Of Bankruptcy
Ownership
Bioatla retains a total of 35.34 Million outstanding shares. The majority of Bioatla outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bioatla to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bioatla. Please pay attention to any change in the institutional holdings of Bioatla as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Bioatla Ownership Details

Bioatla Stock Price Odds Analysis

What are Bioatla's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Bioatla jumping above the current price in 90 days from now is roughly 97.0%. The Bioatla probability density function shows the probability of Bioatla stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.331 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bioatla will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Bioatla is significantly underperforming DOW.
 Odds Down 10.11HorizonTargetOdds Up 10.11 
3.00%90 days
 10.11 
96.99%
Based on a normal probability distribution, the odds of Bioatla to move above the current price in 90 days from now is roughly 97.0 (This Bioatla probability density function shows the probability of Bioatla Stock to fall within a particular range of prices over 90 days) .

Bioatla Historical Income Statement

Bioatla Income Statement is one of the three primary financial statements used for reporting Bioatla's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Bioatla revenue and expense. Bioatla Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Bioatla Gross Profit is projected to decrease significantly based on the last few years of reporting. The past year's Gross Profit was at 386,100. The current year Interest Expense is expected to grow to about 1.6 M, whereas Consolidated Income is forecasted to decline to (34.8 M). View More Fundamentals

Bioatla Stock Against Markets

Picking the right benchmark for Bioatla stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bioatla stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bioatla is critical whether you are bullish or bearish towards Bioatla at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bioatla without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Commodity Channel Index Now

   

Commodity Channel Index

Use Commodity Channel Index to analyze current equity momentum
All  Next Launch Module
Continue to Trending Equities. Note that the Bioatla information on this page should be used as a complementary analysis to other Bioatla's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Bioatla Stock analysis

When running Bioatla price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Is Bioatla's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. If investors know Bioatla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bioatla listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioatla's value and its price as these two are different measures arrived at by different means. Investors typically determine Bioatla value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioatla's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.